Related Experiment Video
Updated: Aug 9, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Early reperfusion strategies after acute ST-segment elevation myocardial infarction: the importance of timing
1Section of Cardiology, University of Chicago, IL 60637, USA. dfaxon@medicine.bsd.uchicago.edu
Insights
Primary angioplasty is the preferred treatment for ST-segment elevation myocardial infarction (STEMI) when timely. Rapid transport to experienced centers improves outcomes for STEMI patients.
Area of Science:
- Cardiology
- Emergency Medicine
- Interventional Cardiology
Background:
- Acute ST-segment elevation myocardial infarction (STEMI) affects over 500,000 people annually in the US.
- Reperfusion therapies like fibrinolysis and primary angioplasty have reduced STEMI mortality.
- Primary angioplasty offers superior outcomes to fibrinolysis when performed promptly by experienced teams.
Purpose of the Study:
- To review the effectiveness of primary angioplasty versus fibrinolysis for STEMI.
- To identify optimal reperfusion strategies based on time, risk, and facility capabilities.
- To emphasize the need for efficient patient transport systems for STEMI care.
Main Methods:
- Review of current literature and clinical guidelines on STEMI reperfusion.
- Comparison of outcomes associated with primary angioplasty and fibrinolysis.
- Analysis of factors influencing treatment decisions and patient outcomes.
Main Results:
- Primary angioplasty is superior to fibrinolysis, especially for symptom onset >3 hours, high-risk patients, and when door-to-balloon time is <90 minutes.
- Transfer to capable facilities for primary angioplasty is safe if delay is <90 minutes.
- Facilitated percutaneous coronary intervention shows promise but has not yet demonstrated mortality benefit.
Conclusions:
- Primary angioplasty is the preferred reperfusion strategy for STEMI in interventional facilities.
- Timely intervention and efficient patient transfer systems are crucial for optimal STEMI outcomes.
- Further research is needed for facilitated percutaneous coronary intervention.
Abstract:
Acute ST-segment elevation myocardial infarction is estimated to occur in more than 500,000 people in the US every year. With the introduction of reperfusion therapy by fibrinolysis or primary angioplasty, mortality has significantly fallen. Although fibrinolysis is more readily available than primary angioplasty, the latter is more effective and results in better short-term and long-term outcomes if performed in a timely manner by an experienced operator and hospital team. The ischemic time, door-to-balloon time and clinical risk are important determinants of favorable outcome. Primary angioplasty is the preferred reperfusion strategy when symptom onset is longer than 3 h, in high-risk patients, such as those with cardiogenic shock, congestive heart failure or elderly age, and those with contraindications for fibrinolysis. Primary angioplasty is the preferred strategy in interventional facilities, with a goal door-to-balloon time of less than 90 min. For patients who present to noninterventional facilities, transfer to a hospital capable of primary angioplasty is safe and effective if the additional treatment delay is less than 90 min. Facilitated percutaneous coronary intervention has been shown in several small trials to offer early vessel patency and improve outcomes compared with fibrinolysis alone, but has not been shown to reduce mortality. Larger trials are ongoing to evaluate the benefit of this approach. The establishment of an effective and efficient system for the rapid transport of patients to centers capable and experienced in primary angioplasty is severely needed to provide optimum treatment and outcomes to patients with ST-segment elevation acute myocardial infarction.
More Related Videos
05:26Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
Acute Coronary Syndrome I: Introduction
Acute Coronary Syndrome III: Diagnostic Studies
Cardiopulmonary Resuscitation IV: Pharmacological Management